DIIVA-MSNCT06495138
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
At risk: Primary completion moved at least 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion dates pushed to Oct 2027
- Eligibility criteria expanded, about 16 words
- Secondary endpoints: details revised at 9 of 9 entries
- Notable Eligibility criteria expanded, about 17 words
- Start date changed from estimate of Apr 2025 to Apr 21, 2025
- Secondary endpoints: details revised at 1 of 9 entries
- Study arms: 2 to 3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Feb 2025 to Apr 2025
- Site details revised
- Notable Start date: Sep 2024 to Feb 2025v3
- Minor Study description revised
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
The dosages of the D-IVA-GSE and I-IVA-GSE are based on the FITT principle of exercise prescription (frequency, intensity, time, and type). The D-IVA-GSE group will perform two, 15- minute GSE sessions (30-minutes total per day), seven days per week.
The I-IVA-GSE group will perform two, 15-minute IVA-GSE sessions (30 minutes total), three days per week, with at least one day between each exercise day.
The healthy control group will complete the same baseline assessments as the subjects in the Multiple Sclerosis (MS) group to serve as normative reference data.
Devices: StableEyes
Sites
1 site in 1 country
- Emory UniveristyAtlanta, Georgia, United States